Keeping organs designated for transplantation cool is vital to ensure procedure success. Medtech Insight spoke to Paragonix’s CEO, Lisa Anderson, to learn more.
Paragonix has developed a range of organ transportation devices to tackle the structural and logistical challenges surrounding organ transplantation.
So far, the Cambridge, MA-based company has developed devices for transporting human hearts, lungs, livers, kidneys and pancreases. It is...
Create an account to read this article
Already a subscriber?
Abbott’s Navitor TAVR system is now CE-marked for low to intermediate risk patients, based on positive data from the Vintage trial. The EACTS guidelines for TAVR lowered the recommended age for patients with severe aortic stenosis to 70 years and older, which opens up treatment for younger patients.
Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.
The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.
The US FDA has provided an update on its breakthrough devices program, now 10 years running. Cardiac, orthopedic, and neurological devices have received the most designations, while only one has been awarded to an obstetrics/gynecology product.
After divesting bone healing products in mid-year, Highridge Medical doubled down on its spine capabilities with a triple purchase of technologies from Accelus, bringing access to “Adaptive Geometry.” CEO Rebecca Whitney explained Highridge’s strategy.
Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.
Abbott’s Navitor TAVR system is now CE-marked for low to intermediate risk patients, based on positive data from the Vintage trial. The EACTS guidelines for TAVR lowered the recommended age for patients with severe aortic stenosis to 70 years and older, which opens up treatment for younger patients.
